Obstetrics & Gynecology:
Relationships Between Cell-Free DNA and Serum Analytes in the First and Second Trimesters of Pregnancy
Vora, Neeta L. MD; Johnson, Kirby L. PhD; Lambert-Messerlian, Geralyn PhD; Tighiouart, Hocine MS; Peter, Inga PhD; Urato, Adam C. MD; Bianchi, Diana W. MD
From the Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts; the Division of Genetics, Department of Pediatrics, Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts; the Department of Pathology and Laboratory Medicine, Women and Infants Hospital and the Alpert School of Medicine at Brown University, Providence, Rhode Island; the Institute of Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; and the Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York.
Corresponding author: Kirby L. Johnson, MD, Floating Hospital for Childen at Tufts Medical Center, Division of Genetics, Department of Pediatrics, Box 394, 800 Washington Street, Boston, MA 02111; e-mail: firstname.lastname@example.org.
Supported by National Institutes of Health grants T32 HD049341 and HD42053-07.
Financial Disclosure Dr. Bianchi is a member of the Clinical Advisory Board and she holds equity in Artemis Health, Inc. Artemis Health had no role in the design or conduct of this study.
OBJECTIVE: To assess the relationship between first- and second-trimester cell-free DNA levels and maternal serum screening markers.
METHODS: First- and second-trimester residual maternal serum samples from 50 women were obtained. First-trimester (pregnancy-associated plasma protein A and β-hCG) and second-trimester serum analytes (β-hCG, alpha-fetoprotein, unconjugated estriol, and inhibin A) had been measured at the time of sample receipt. All fetuses were male as confirmed by birth records. Cell-free DNA was extracted and measured by real-time quantitative polymerase chain reaction amplification using glyceraldehyde phosphate dehydrogenase and DYS1 as markers of total DNA and fetal DNA, respectively. Determination of linear associations between first- and second-trimester serum markers and cell-free DNA levels using Pearson correlations was performed.
RESULTS: Statistically significant correlations between first-trimester pregnancy-associated plasma protein A multiples of the median and both total (r=0.36, P=.016) and fetal (r=0.41, P=.006) DNA in the first trimester were observed. There were no significant correlations between first-trimester serum human chorionic gonadotropin or any second-trimester serum marker with DNA levels.
CONCLUSION: Correlation between serum pregnancy-associated plasma protein A and first-trimester circulating cell-free fetal and total DNA levels is a novel finding. Pregnancy-associated plasma protein A is a glycoprotein of placental origin, and its correlation to cell-free fetal DNA in maternal serum suggests a common tissue origin through apoptosis of placental cells. However, because pregnancy-associated plasma protein A and cell-free DNA were only marginally correlated and cell-free DNA can be reliably detected in the first trimester, the addition of cell-free DNA to serum screening strategies may be helpful in predicting adverse pregnancy outcome.
LEVEL OF EVIDENCE: II
Maternal serum is routinely analyzed in pregnant women to screen for chromosomal abnormalities such as Down and Edwards syndromes and neural tube defects. In addition, there are many reports of an association between abnormal levels of individual analytes and poor fetal or placental health. For example, although elevated alpha-fetoprotein in the second trimester indicates a high risk of neural tube and ventral wall defects, it is also reported to be associated with other fetal abnormalities and adverse obstetric outcomes, such as intrauterine growth restriction.1 Similarly, a low pregnancy-associated plasma protein A (PAPP-A) in the first trimester indicates a high risk for Down and Edwards syndromes and is associated with poor pregnancy outcomes, such as preterm delivery, fetal growth restriction, and spontaneous loss.1,2 Although informative in the first trimester, PAPP-A has not been shown to be useful in the second trimester because its level does not differ between unaffected fetuses and fetuses with Down syndrome during this time.3 The second-trimester serum markers of placental origin, β-hCG and inhibin A, can also be elevated in pregnancies with adverse outcomes.1
Circulating cell-free fetal DNA is released into the maternal circulation as a result of placental apoptosis.4,5 Increased levels of cell-free fetal DNA are associated with abnormal placental development.6 Cell-free fetal DNA is elevated in pregnancies with fetal Down syndrome7–10 and has been suggested as an additional serum marker to improve detection.10 Cell-free fetal DNA levels are also increased in other complications of pregnancy that involve the placenta, such as preeclampsia, intrauterine growth restriction, and invasive placentation.11–17 Thus, both Down syndrome and abnormal placentation appear to cause a change in serum analytes and an increase in cell-free fetal DNA.
Because cell-free DNA and maternal serum markers are thought to be indicators of fetal and placental health, our goal was to assess the relationship between first- and second-trimester serum analytes and cell-free fetal and total DNA levels toward potential future improvements to serum screening.
MATERIALS AND METHODS
This study was approved by the Institutional Review Boards at Women and Infants' Hospital and Tufts Medical Center. First- and second-trimester residual maternal serum samples from 50 women were randomly selected and obtained between February and May 2007 from routine prenatal screening in the Department of Pathology and Laboratory Medicine at Women and Infants' Hospital without regard to results. First trimester was defined as between 10 3/7 weeks and 13 6/7 weeks of gestation; second trimester was between 15 and 20 completed weeks of gestation. Only samples collected from a pregnancy resulting in the birth of a singleton male were selected using birth records to confirm the sex. Birth outcomes (eg, karyotype) were not determined because the objective of the study was to compare serum analytes with cell-free DNA levels toward potential future improvements to serum screening. Multiple gestations, women with insulin-dependent diabetes, and pregnancies resulting from in vitro fertilization were excluded. Serum analytes (PAPP-A, β-hCG, alpha-fetoprotein, unconjugated estriol, and inhibin A) were measured at the time of sample receipt using the Access Immunoassay System (Beckman Coulter, Inc, Brea, CA). Total β-hCG was measured on first-trimester serum samples at the time of the present study, and an aliquot was prepared on sample thaw for DNA testing.
Cell-free DNA was extracted from all samples and measured by real-time quantitative polymerase chain reaction amplification as previously described.18,19 DNA was extracted from 400 microliters of serum using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the blood and body fluid protocol. DNA was eluted in 50 microliters of the elution buffer. Real-time quantitative polymerase chain reaction amplification was performed to amplify the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase to show that DNA had been successfully extracted from the serum sample. Polymerase chain reaction amplification of DYS1, a Y chromosome sequence, was used to detect male DNA. All samples were analyzed in triplicate. DNA analysis was performed in Boston on samples coded in Rhode Island. A female staff member processed and handled all samples to minimize the risk of contaminating samples with male DNA. Additional variables included maternal age and weight, gestational age, parity, and smoking (Table 1). Determination of linear associations between first- and second-trimester cell-free DNA and serum markers within and across trimesters using Pearson correlations was performed. Multiples of the median were log-transformed and correlation coefficients were calculated. Both cell-free DNA and serum markers were adjusted for maternal weight using partial correlations. The minimum correlation that can be detected when n=50 at α=0.05 and with a power of 0.80 is r=0.39 using Fisher's z transformation. Statistical significance was assigned when P<.05.
Both glyceraldehyde-3-phosphate dehydrogenase and DYS1 were detected and amplified in all samples; therefore, the sensitivity of detection of both markers was 100%. In the first trimester, statistically significant correlations were observed between PAPP-A multiples of the median and both total (r=0.36, P=.016) and fetal (r=0.41, P=.006) DNA levels (Table 2). Neither DYS1 nor glyceraldehyde-3-phosphate dehydrogenase levels correlated significantly with any of the other measured analytes (Table 3). First-trimester DYS1 and second-trimester DYS1 levels were significantly correlated (r=0.37, P=.015). It is not known if this relationship holds across all maternal and gestational ages, because the sample size is too small to conduct subgroup analysis for these variables.
Our objective was to examine the relationship between cell-free DNA levels and serum markers in both first and second trimesters of pregnancy. Our analysis demonstrates that there is a marginal, yet statistically significant, correlation between first-trimester serum PAPP-A and first-trimester cell-free and total DNA levels. Both are markers of placental function, because PAPP-A is a glycoprotein of placental origin, and cell-free DNA in maternal serum derives predominantly from apoptosis of placental cells.
Concerning the biological plausibility for the correlation between PAPP-A and cell-free DNA, PAPP-A is a protease for insulin growth factor–binding protein 4. Lower levels of PAPP-A are associated with higher levels of insulin growth factor–binding protein 4, and thus, less free insulin growth factor. Insulin growth factor regulates fetal growth by stimulating cell proliferation and differentiation and plays a role in trophoblast invasion of the decidua.20,21 Cell-free DNA is thought to be mainly released from the placenta and is a result of trophoblastic apoptosis.5,22 If there is abnormal trophoblast invasion in early pregnancy and decreased subsequent cell proliferation, this could result in poor placental development and an increase in placental apoptosis, which would then result in high cell-free DNA levels with correspondingly low PAPP-A levels. Further studies are needed to test this hypothesis.
This study shows an early marginal correlation in the first trimester between PAPP-A and cell-free fetal DNA. In the second trimester, total and fetal DNA are not correlated with any of the serum analytes, even the analytes specifically of placental origin. This is surprising given that the source of fetal DNA measured in the maternal circulation is hypothesized to predominantly originate from the placenta. These results raise the question of extraplacental sources of fetal DNA and suggest that such sources may differ between trimesters. This possibility warrants further investigation as to the source of cell-free DNA throughout pregnancy.
Prior reports in the literature demonstrate that a low PAPP-A value and a high cell-free fetal DNA measurement are both associated with adverse pregnancy outcomes. Results from the First and Second Trimester Evaluation of Risk (FASTER) trial showed that a PAPP-A measurement of less than the fifth percentile was associated with spontaneous pregnancy loss at less than 24 weeks of gestation, preeclampsia, low birth weight, gestational hypertension, preterm birth, stillbirth, preterm premature rupture of membranes, and placental abruption.20 Low PAPP-A and high DNA levels both suggest placental abnormalities. Future work is needed to determine whether this correlation has clinical significance. Although abnormal serum markers are indicators of poor placental health and are associated with adverse pregnancy outcomes, there is no currently accepted practice for managing pregnancies in women with abnormal serum markers. Because cell-free fetal DNA can be detected in the first trimester, it may have use, in conjunction with other analytes, as an early marker of adverse obstetric outcomes.23
Markers in serum screening have been chosen based on their ability to provide independent information. Low correlation between serum markers is required to improve Down syndrome detection rates.24,25 Addition of fetal DNA as a marker of Down syndrome may improve screening performance, especially in the second trimester when all correlations are low. On the other hand, recent strategies have emerged in screening to take advantage of high correlations of marker levels. High correlation of a marker across trimesters can be used to improve prenatal screening for Down syndrome by calculating ratios of the levels of the same serum markers measured in the first and the second trimester (cross-trimester ratios).26 Use of cross-trimester ratios was also found to improve the performance of the integrated screening test and lower the false-positive rate.26 We found a statistically significant correlation between cell-free fetal DNA in the first and second trimesters (P=.015). Future work studying cell-free DNA levels across trimesters can be done to determine whether this could improve screening performance. However, the use of cell-free fetal DNA can ultimately only be realized with a gender-independent marker. In this study, a Y chromosome sequence was used a marker of fetal DNA, meaning that only half of pregnancies can be analyzed. Although these data show the feasibility of using cell-free DNA as a biomarker, a gender-independent marker is essential for widespread clinical implementation.
The correlation of second-trimester serum markers and fetal DNA has been examined in a prior study.10 Our results are in agreement that the correlation of markers is low. The correlation (r) of alpha-fetoprotein, unconjugated estriol, or β-hCG with fetal DNA ranged from 0.1 to 0.2 in both studies. The results for inhibin were more variable: 0.3 in the prior study but −0.09 presently. Nevertheless, either of these correlations is low enough to suggest a benefit from addition of fetal DNA levels to second-trimester screening. Indeed, Farina et al10 calculated that fetal DNA measurement could add 5% detection to second-trimester Down syndrome screening over routine quad markers alone.
A limitation of the study is that pregnancy outcomes were not determined other than to confirm that there was a birth of a liveborn singleton male. However, the objective of the study was to compare serum analytes with cell-free DNA levels toward potential future improvements to serum screening and not to assess for pregnancy outcome. In addition, as a result of the small sample, it is possible that marginal correlations that were reported (ie, correlation of cell-free fetal DNA and PAPP-A) or those that were undiscovered would be further delineated from a larger sample size. Nevertheless, there are a number of strengths in our study. We used the same patients for the first- and second-trimester data, 98% of patients were nonsmokers, and in vitro fertilization patients were excluded. Prior data has shown that smoking in pregnancy increases levels of total cell-free DNA threefold.27 In addition, although one study has shown that in vitro fertilization does not affect levels of cell-free fetal DNA,28 these pregnancies were excluded because some studies suggest that serum analytes in pregnancies conceived with assisted reproductive technologies may be abnormal.29
Our observation that PAPP-A and cell-free DNA are correlated in the first trimester reinforces the idea of cell-free DNA as a marker of placental development. Further studies should be done to determine whether pregnancies with abnormal placentas show an increase in trafficking of total and fetal DNA and whether this increase correlates with other placental secretory products. If patients with abnormally low PAPP-A and high cell-free DNA levels have poor pregnancy outcomes, these combined markers could potentially identify pregnancies in the first trimester that warrant increased surveillance.
1. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008;30:918–49.
2. Montanari L, Alfei A, Albonico G, Moratti R, Arossa A, Beneventi F, et al. The impact of first-trimester serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A on the diagnosis of fetal growth restriction and small for gestational age infant. Fetal Diagn Ther 2009;25:130–5.
3. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56–104.
4. Bischoff FZ, Lewis DE, Simpson JL. Cell-free fetal DNA in maternal blood: kinetics, source and structure. Hum Reprod Update 2005;11:59–67.
5. Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW, Burton GJ. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006;169:400–4.
6. Maron JL, Bianchi DW. Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress. Am J Med Genet C Semin Med Genet 2007;145C:5–17.
7. Lo YM, Lau TK, Zhang J, Leung TN, Chang AM, Hjelm NM, et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem 1999;45:1747–51.
8. Zhong XY, Burk MR, Troeger C, Jackson LR, Holzgreve W, Hahn S. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses. Prenat Diagn 2000;20:795–8.
9. Lee T, LeShane ES, Messerlian GM, Canick JA, Farina A, Heber WW, et al. Down syndrome and cell-free fetal DNA in archived maternal serum. Am J Obstet Gynecol 2002;187:1217–21.
10. Farina A, LeShane ES, Lambert-Messerlian G, Canick J, Lee T, Neuveux L, et al. Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. Clin Chem 2003;49:239–42.
11. Alberry MS, Maddocks DG, Hadi MA, Metawi H, Hunt LP, Abdel-Fattah SA, et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009;200:98.e1–6.
12. Leung TN, Zhang J, Lau TK, Chan LY, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001;47:137–9.
13. Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update 2009;15:139–51.
14. Hahn S, Huppertz B, Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? Placenta 2005;26:515–26.
15. Al Nakib M, Desbrière R, Bonello N, Bretelle F, Boubli L, Gabert J, et al. Total and fetal cell-free DNA analysis in maternal blood as markers of placental insufficiency in intrauterine growth restriction. Fetal Diagn Ther 2009;26:24–8.
16. Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184–8.
17. Caramelli E, Rizzo N, Concu M, Simonazzi G, Carinci P, Bondavalli C, et al. Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction—a pilot study. Prenat Diagn 2003;23:367–71.
18. Johnson KL, Dukes KA, Vidaver J, LeShane ES, Ramirez I, Weber WD, et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem 2004;50:516–21.
19. Wataganara T, Bianchi DW. Fetal cell-free nucleic acids in the maternal circulation: new clinical applications. Ann N Y Acad Sci 2004;1022:90–9.
20. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004;191:1446–51.
21. Byun D, Mohan S, Yoo M, Sexton C, Baylink DJ, Qin X. Pregnancy-associated plasma protein-A accounts for the insulin like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro. J Clin Endocrinol Metab 2001;86:847–54.
22. Alberry M, Maddocks D, Jones M, Abdel Hadi M, Abdel-Fattah S, Avent N, et al. Free fetal DNA in maternal plasma in anembryonic pregnancies; confirmation that the origin is the trophoblast. Prenat Diagn 2007;27:415–8.
23. Dugoff L; Society for Maternal–Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010;115:1052–61.
24. Wright DE, Bradbury I. Repeated measures screening for Down's Syndrome. BJOG 2005;112:80–3.
25. Wald NJ, Bestwick JP, Morris JK. Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenat Diagn 2006;26:514–23.
26. Urato AC, Peter I, Canick J, Lambert-Messerlian G, Pulkkinen A, Knight G, et al. Smoking in pregnancy is associated with increased total maternal serum cell-free DNA levels. Prenat Diagn 2008;28:186–90.
27. Pan PD, Peter I, Lambert-Messerlian GM, Canick JA, Bianchi DW, Johnson KL. Cell-free fetal DNA levels in pregnancies conceived by IVF. Hum Reprod 2005;20:3152–6.
28. Henionen S, Ryynanen M, Kierkinen P, Hippelainen M, Saarikoski S. Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down's syndrome screening. Fertil Steril 1996;66:398–403.
29. Hui PW, Lam YH, Tang MH, Ng EH, Yeung WS, Ho PC. Maternal serum pregnancy-associated plasma protein-A and free beta-human chorionic gonadotrophin in pregnancies conceived with fresh and frozen-thawed embryos from in vitro fertilization and intracytoplasmic sperm injection. Prenat Diagn 2005;25:390–3.
Figure. No caption available.
© 2010 by The American College of Obstetricians and Gynecologists.